絞り込み

17876

広告

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

著者 Blanke CD , Demetri GD , von Mehren M , Heinrich MC , Eisenberg B , Fletcher JA , Corless CL , Fletcher CD , Roberts PJ , Heinz D , Wehre E , Nikolova Z , Joensuu H
J Clin Oncol.2008 Feb 1 ; 26(4):620-5.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Oregon Health and Science University Cancer Center and Portland Veterans Affairs Hospital, Portland, OR, USA. blankec@ohsu.edu

スターを付ける スターを付ける     (111view , 0users)

Full Text Sources

Medical

Other Literature Sources

The outcome of patients diagnosed with advanced gastrointestinal stromal tumor (GIST) and treated long-term with imatinib mesylate is unknown. A previous report of a randomized phase II trial of imatinib mesylate in patients with incurable GIST detailed high response rates at both the 400 and the 600 mg/d dose levels. We conducted a long-term analysis of patients treated on the trial, including patients followed during an extension phase, to evaluate survival, patterns of failure, and potential prognostic factors, including tumor mutational status.
PMID: 18235121 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード